白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
JOURNAL OF LEUKEMIA & LYMPHOMA
2012年
10期
601-603
,共3页
利妥昔单抗%复发%难治%淋巴瘤,大B-细胞,弥漫性
利妥昔單抗%複髮%難治%淋巴瘤,大B-細胞,瀰漫性
리타석단항%복발%난치%림파류,대B-세포,미만성
Rituximab%Relapse%Refractory%Diffuse large B cell lymphoma
目的 观察R-CHOP方案治疗复发、难治弥漫大B细胞淋巴瘤(DLBCL)的临床疗效及患者不良反应.方法 选择30例经病理证实为CD20阳性的DLBCL患者,前期常规方案化疗(不含利妥昔单抗)2～6个疗程后评估为复发或难治患者,其中复发患者16例,难治患者14例.应用R-CHOP方案治疗4～6个周期,每个周期21 d.所有淋巴瘤患者均为Ⅲ～Ⅳ期,搜集治疗前后相关临床资料,采用回顾性分析方法,将R-CHOP方案疗效与文献及自身对照比较,评价其疗效及不良反应.结果 全组30例患者均可评价疗效,完全缓解15例,部分缓解10例,稳定3例,进展2例,完全缓解率为50.0％(15/30),总有效率83.3 ％(25/30).出现Ⅱ度白细胞减少3例,Ⅰ度血小板降低1例,恶心等轻微的消化道反应2例.结论 R-CHOP方案对复发、难治DLBCL仍有良好的治疗效果,完全缓解率与总有效率明显优于常规二线化疗方案.接受R-CHOP方案治疗患者不良反应轻微,与常规化疗方案无显著区别,患者耐受良好.
目的 觀察R-CHOP方案治療複髮、難治瀰漫大B細胞淋巴瘤(DLBCL)的臨床療效及患者不良反應.方法 選擇30例經病理證實為CD20暘性的DLBCL患者,前期常規方案化療(不含利妥昔單抗)2～6箇療程後評估為複髮或難治患者,其中複髮患者16例,難治患者14例.應用R-CHOP方案治療4～6箇週期,每箇週期21 d.所有淋巴瘤患者均為Ⅲ～Ⅳ期,搜集治療前後相關臨床資料,採用迴顧性分析方法,將R-CHOP方案療效與文獻及自身對照比較,評價其療效及不良反應.結果 全組30例患者均可評價療效,完全緩解15例,部分緩解10例,穩定3例,進展2例,完全緩解率為50.0％(15/30),總有效率83.3 ％(25/30).齣現Ⅱ度白細胞減少3例,Ⅰ度血小闆降低1例,噁心等輕微的消化道反應2例.結論 R-CHOP方案對複髮、難治DLBCL仍有良好的治療效果,完全緩解率與總有效率明顯優于常規二線化療方案.接受R-CHOP方案治療患者不良反應輕微,與常規化療方案無顯著區彆,患者耐受良好.
목적 관찰R-CHOP방안치료복발、난치미만대B세포림파류(DLBCL)적림상료효급환자불량반응.방법 선택30례경병리증실위CD20양성적DLBCL환자,전기상규방안화료(불함리타석단항)2～6개료정후평고위복발혹난치환자,기중복발환자16례,난치환자14례.응용R-CHOP방안치료4～6개주기,매개주기21 d.소유림파류환자균위Ⅲ～Ⅳ기,수집치료전후상관림상자료,채용회고성분석방법,장R-CHOP방안료효여문헌급자신대조비교,평개기료효급불량반응.결과 전조30례환자균가평개료효,완전완해15례,부분완해10례,은정3례,진전2례,완전완해솔위50.0％(15/30),총유효솔83.3 ％(25/30).출현Ⅱ도백세포감소3례,Ⅰ도혈소판강저1례,악심등경미적소화도반응2례.결론 R-CHOP방안대복발、난치DLBCL잉유량호적치료효과,완전완해솔여총유효솔명현우우상규이선화료방안.접수R-CHOP방안치료환자불량반응경미,여상규화료방안무현저구별,환자내수량호.
Objective To evaluate the clinical efficacy and toxicity of rituximab combined with CHOP (R-CHOP) in the treatment of relapsed or refractory diffuse large B cell lymphoma (DLBCL).Methods 30 patients were enrolled.All patients,pathologically confirmed to be CD20 positive DLBCL (all in stages Ⅲ-Ⅳ ), were relapsed or refractory after received 2-6 cycles of chemotherapy. Then all of them received R-CHOP schedule for 4 to 6 cycles, each cycle was 21 days. Clinical data before and after R-CHOP were collected.A retrospective analysis of the R-CHOP therapy,either compared to the literature or self-control was performed to evaluate the efficacy and toxicity. Results All the 30 patients were evaluable, induding 15 cases were complete remission (CR), 10 cases were partial remission (PR), 3 cases were stable disease (SD),and 2 cases were progressed disease (PD).The CR rate was 50.0 ％ (15/30),the total response rate (RR) was 83.3 ％ (25/30).All patients were well tolerated to the therapy.Only 3 cases were Ⅱ degree neutropenia,1 case was Ⅰ degree thrombocytopenia, and 2 cases suffered nausea and other mild gastrointestinal discomfort. Conclusions R-CHOP regimen could also achieve good response for relapsed or refractory DLBCL significantly.The common adverse effects of rituximab were mild.All the patients were well tolerated.
